December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,181.32 -25.95 (-2.15%)
Streaming Delayed Price Updated: 3:01 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger ↗
The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker. 
Via The Motley Fool
News headline image
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? ↗
Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year. 
Via The Motley Fool
Topics ETFs
News headline image
Amphastar (AMPH) Q2 2026 Earnings Call Transcript ↗
New product launches drove 5% revenue growth and margin expansion. 
Via The Motley Fool
Topics Earnings
Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup ↗
Via Chartmill
Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup ↗
Via Chartmill
News headline image
Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now? ↗
Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or Simplify's Actively Managed PINK? ↗
Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity ↗
The stock continues to look unstoppable. 
Via The Motley Fool
News headline image
Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating? ↗
It's yet another setback for the drugmaker. 
Via The Motley Fool
News headline image
IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play? ↗
FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly (LLY) Q2 2026 Earnings Call Transcript ↗
Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised. 
Via The Motley Fool
Topics Earnings
News headline image
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities ↗
Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks. 
Via Benzinga
Topics Law Enforcement Lawsuit
News headline image
1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run ↗
It has proven to be a market-beater in more years than not. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited grow... 
Via StockStory
Topics Earnings
News headline image
Better Buy: Eli Lilly vs. Novo Nordisk ↗
Novo Nordisk is playing catch-up in the GLP-1 race. 
Via The Motley Fool
News headline image
Absci Q2 Earnings Call Highlights ↗
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis,... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now ↗
SpaceX has attractive prospects, but the market has already factored that into its share price. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy ↗
Omada Health (NASDAQ:OMDA) highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic... 
Via MarketBeat
News headline image
2 S&P 500 Stocks with Exciting Potential and 1 We Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Stocks
News headline image
Why Eli Lilly Topped the Market Today ↗
One of its more popular products just got the green light from a major national regulator. 
Via The Motley Fool
News headline image
Eli Lilly Upgraded, Best Buy Downgraded: Updated Rankings on Top Blue-Chip Stocks ↗
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. 
Via InvestorPlace
News headline image
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? ↗
It's not much of a rivalry yet. 
Via The Motley Fool
News headline image
iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond? ↗
XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly and Company Q2 Earnings Call Highlights ↗
Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising... 
Via MarketBeat
Topics Earnings
News headline image
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗
XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem ↗
Can anyone take the top spot away from Eli Lilly in the anti-obesity area? 
Via The Motley Fool
News headline image
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗
Berobenatide is one of the keys to Pfizer's future. 
Via The Motley Fool
News headline image
Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’ ↗
Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lilly to acquire AtaiBeckley for $3.8B. 
Via Benzinga
News headline image
Every S&P 500 Sector ETF Ranked by How Much It Actually Depends on Just 3 Stocks ↗
Sector ETFs give the impression of diversification. Most of them don't have it. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.